×
About 3,243 results

ALLMedicine™ Anaplastic Large Cell Lymphoma Center

Research & Reviews  957 results

Thirty Years of Experience With Ocular Adnexal T-Cell Lymphoma.
https://doi.org/10.1097/IOP.0000000000002309
Ophthalmic Plastic and Reconstructive Surgery; Manta AI, Wilson-Pogmore AA et. al.

Feb 3rd, 2023 - To evaluate the disease characteristics and survival of patients with ocular adnexal T-cell lymphoma. A retrospective, observational study of patients with a histopathological diagnosis of T-cell lymphoma of the ocular adnexa seen between 1992 and...

Patient Decision Making for Management of Style 410 Anatomic Implants in Breast Reconst...
https://doi.org/10.1097/PRS.0000000000009901
Plastic and Reconstructive Surgery; Boyd CJ, Salibian AA et. al.

Feb 3rd, 2023 - In July of 2019, the Food and Drug Administration (FDA) recalled the Allergan Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Textured Breast Implants (Allergan, Santa Barbara, CA) because of a heightened risk of developing breas...

Risk of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in Patients...
https://doi.org/10.1097/PRS.0000000000010195
Plastic and Reconstructive Surgery; Nelson JA, McKernan CD et. al.

Feb 3rd, 2023 - The association between textured implants and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is well established, but the risk of BIA-ALCL in patients with transient exposure to a textured tissue expander (TE) is not as well d...

When a Lump is More Than Just a Lump: Anaplastic Large Cell Lymphoma Presenting as a Pe...
https://doi.org/10.1097/MPH.0000000000002615
Journal of Pediatric Hematology/oncology; Xu S, Duarte LS et. al.

Jan 31st, 2023 - Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin T-cell lymphoma characterized by a cluster of differentiation-30 positivity. Subtypes are characterized by positive or negative anaplastic lymphoma kinase (ALK) expression. ALCLs account ...

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Jan 25th, 2023 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

see more →

Guidelines  6 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anap...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.

Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated...
https://doi.org/10.1093/asj/sjw259
Aesthetic Surgery Journal; Clemens MW, Horwitz SM

Feb 12th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  78 results

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Jan 25th, 2023 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular Contracture
https://clinicaltrials.gov/ct2/show/NCT05017337

Jan 19th, 2023 - BASILICA is a translational research study being undertaken at The Royal Marsden NHS Foundation Trust that aims to investigate aetiology of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), capsular contracture (CC) as well as t...

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03049449

Jan 18th, 2023 - Background: Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed. T cells can be genetically mo...

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01979536

Jan 3rd, 2023 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03947255

Dec 8th, 2022 - This is a study to determine the safety and efficacy of brentuximab vedotin in subjects with classic Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T cell lymphoma (PTCL) who experien...

see more →

News  251 results

FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL
https://www.onclive.com/view/fda-grants-fast-track-designation-to-mt-101-for-cd5-relapsed-refractory-ptcl

Nov 21st, 2022 - The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma (PTCL), according to an announcement from Myeloid Therapeutics, Inc.1...

From B to T: a Case of Concurrent B-Cell and T-Cell Lymphomas Successfully Palliated With Targeted Therapies
https://www.mdedge.com/fedprac/avaho/article/257685/lymphoma-plasma-cell-disorders/b-t-case-concurrent-b-cell-and-t-cell
John Esther, Shashank Sama et. al.

Sep 9th, 2022 - Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive type of non- Hodgkin lymphoma (NHL), comprising 30% of all NHL. Due to a decreased state of immunosurveillance resulting from the disease itself and its associated ther.

Tolinapant Displays Encouraging Activity and Safety in Relapsed/Refractory PTCL/CTCL
https://www.onclive.com/view/tolinapant-displays-encouraging-activity-and-safety-in-relapsed-refractory-ptcl-ctcl

Aug 31st, 2022 - Single-agent tolinapant (ASTX660) generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), according to data from the phase 2 A...

Brentuximab Vedotin Boosts Survival in Adult and AYA Patients with Advanced Hodgkin Lymphoma
https://www.onclive.com/view/brentuximab-vedotin-boosts-survival-in-adult-and-aya-patients-with-advanced-hodgkin-lymphoma

Jul 21st, 2022 - Findings from recent studies have demonstrated the value of brentuximab vedotin (Adcetris) in both adult and adolescent and young adult (AYA) patients with advanced Hodgkin lymphoma, Ann S. LaCasce, MD, MMSC, said during a presentation at the 2022...

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL
https://www.onclive.com/view/dr-mehta-shah-on-the-variations-of-the-chop-regimen-in-ptcl

Jul 20th, 2022 - Neha Mehta-Shah, MD, MSCI, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, and medical oncologist, Siteman Cancer Center, discusses variations of CHOP-based c...

see more →

Patient Education  2 results see all →